1887

Chapter 22 : Inhibitors of DNA-Dependent RNA Polymerase

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Inhibitors of DNA-Dependent RNA Polymerase, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817794/9781555812584_Chap22-1.gif /docserver/preview/fulltext/10.1128/9781555817794/9781555812584_Chap22-2.gif

Abstract:

The clinically useful rifamycins include rifampin (known in some countries as rifampicin), a semisynthetic derivative of rifamycin B. Rifamycin B and structurally related antibiotics inhibit bacterial RNA synthesis by binding to the β-subunit of bacterial DNA-dependent RNA polymerases. A section of the chapter provides an overview of transcription in bacteria and the structure and function of bacterial DNA-dependent RNA polymerase. In the initiation phase of RNA synthesis on a duplex DNA template, the RNA polymerase binds at a specific site on the DNA called the promoter. Here, it unwinds and unpairs a small segment of DNA. Rifamycins are characterized by an aliphatic ansa-bridge that connects two nonadjacent positions of a naphthalenic nucleus. Rifamycin SV can be obtained by chemical modification of other rifamycins but is also produced by fermentation of some strains of A. mediterranei. The rifamycins are biologically active against gram-positive bacteria and mycobacteria, particularly Mycobacterium tuberculosis, the agent of tuberculosis. The mechanism of action of rifabutin against M. avium is unknown; in some other susceptible bacteria, this antibiotic inhibits DNA-dependent RNA polymerase. Rifapentine, like other rifamycins, inhibits DNA-dependent RNA polymerase. In addition to its activity against M. tuberculosis, it is active in vitro against M. avium and Toxoplasma gondii. Strains of M. tuberculosis resistant to rifamycin are also resistant to rifapentine. A major advantage of rifapentine over rifampin is that only twice-weekly doses of rifapentine are required for initial treatment of tuberculosis and once-weekly doses are needed during the continuation phase of treatment.

Citation: Mascaretti O. 2003. Inhibitors of DNA-Dependent RNA Polymerase, p 289-293. In Bacteria versus Antibacterial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555817794.ch22
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 22.1
Figure 22.1

Reaction catalyzed by DNA-dependent RNA polymerase. For simplicity, B represents a base and hydrogen bonding between bases is designated by a single dashed line.

Citation: Mascaretti O. 2003. Inhibitors of DNA-Dependent RNA Polymerase, p 289-293. In Bacteria versus Antibacterial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555817794.ch22
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 22.2
Figure 22.2

Chemical structures of rifamycins B and SV, rifampin, and rifapentine.

Citation: Mascaretti O. 2003. Inhibitors of DNA-Dependent RNA Polymerase, p 289-293. In Bacteria versus Antibacterial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555817794.ch22
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555817794.chap22
1. Horton, H. R.,, L. A. Moran,, R. S. Ochs,, J. D. Rawn,, and K. G. Scrimgeour. 2002. Principles of Biochemistry, 3rd ed. Prentice-Hall, Englewood Cliffs, N.J.
2. Nelson, D. L.,, and M. M. Cox. 2000. Lehninger Principles of Biochemistry, 3rd ed. Worth Publishers, New York, N.Y.
3. Zubay, G. L. 1998. Biochemistry, 4th ed. Wm. C. Brown Publishers, Dubuque, Iowa.
4. Dollery, C. 1999. Therapeutic Drugs, 2nd ed., p. R32R37. Churchill Livingstone, Edinburgh, United Kingdom.
5. Honore, N.,, and S. T. Cole. 1993. Molecular basis of rifampin resistance in Mycobacterium leprae. Antimicrob. Agents Chemother. 37:414418.
6. Miller, L. P.,, J. T. Crawford,, and T. M. Shinnick. 1994. The rpoB gene of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38:805811.
7. Moghazeh, S. L.,, X. Pan,, T. Arain,, C. K. Stover,, J. M. Musser,, and B. N. Kreiswirth. 1996. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob. Agents Chemother. 40:26552657.
8. Telenti, A.,, P. Imboden,, F. Marchesi,, D. Lowrie,, S. Cole,, M. J. Colston,, L. Matter,, K. Schopfer,, and T. Bodmer. 1993. Detection of rifampicin-resistant mutations in Mycobacterium tuberculosis. Lancet 341:664665.
9. Valim, A. R.,, M. L. Rossetti,, M. O. Ribeiro,, and A. Zaha. 2000. Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from Brazil. J. Clin. Microbiol. 38:31193122.
10. Williams, D. L.,, L. Spring,, L. Collins,, L. P. Miller,, L. B. Heifets,, P. R. J. Gangadharam,, and T. P. Gillis. 1998. Contribution of rpoB mutations to development of rifamycin crossresistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42:18531857.
11. Musser, J. M. 1995. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin. Microbiol. Rev. 8:495514.
12. Anonymous. 1993. Rifabutin. Med. Lett. 35:893899.
13. Dautzenberg, B.,, P. Castellani,, J. L. Pellegrin,, D. Vittecoq,, C. Truffot-Pernot,, N. Pirotta,, and D. Sassella. 1996. Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients. Antimicrob. Agents Chemother. 40:17221725.
14. Dollery, C. 1999. Therapeutic Drugs, 2nd ed., p. R26R32. Churchill Livingstone, Edinburgh, United Kingdom.
15. Anonymous. 1999. Rifapentine. Med. Lett. 41:2122.
16. Araujo, F. G.,, A. A. Khan,, and J. S. Remington. 1996. Rifapentine is active in vitro and in vivo against Toxoplasma gondii. Antimicrob. Agents Chemother. 40:13351337.

Tables

Generic image for table
Table 22.1

Generic and common trade names of rifamycins and the preparations available in the United States a

Citation: Mascaretti O. 2003. Inhibitors of DNA-Dependent RNA Polymerase, p 289-293. In Bacteria versus Antibacterial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555817794.ch22

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error